MedTrace Logo

GoalTracker: Comparing Self-Monitoring Strategies for Weight Loss

NCT03254953 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2018-04-25

No results posted yet for this study

Summary

This study is a randomized controlled trial that compares 3 self-monitoring approaches for weight loss. GoalTracker is a standalone, technology-based intervention using a commercial smartphone app (MyFitnessPal) and email.

The investigators hypothesize that the group that delays diet tracking and receives additional intervention components (weekly personalized feedback, skills training, and action plans) will have greater weight loss at the end of the 12-week intervention and at 6-month followup, compared to (a) an intervention group that simultaneously tracks weight and diet for all 12 weeks and receives the same additional components, and (b) a control group that tracks only diet.

Conditions

Interventions

BEHAVIORAL

self-monitoring of body weight

\- weigh daily for 3 months and track their weight using the MyFitnessPal mobile app

BEHAVIORAL

self-monitoring of diet

* track their diet (food and drinks) daily using the MyFitnessPal mobile app * when they are asked to track diet will vary based on the arm

BEHAVIORAL

weekly personalized feedback + lessons + action plans

\- these are additional evidence-based intervention components

Sponsors & Collaborators

Principal Investigators

  • Michele G Lanpher, MA · Duke University

  • Gary G Bennett, PhD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-19
Primary Completion
2017-12-11
Completion
2018-03-02

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03254953 on ClinicalTrials.gov